Overview

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.
Phase:
Phase 2
Details
Lead Sponsor:
Seagen Inc.
Seattle Genetics, Inc.
Collaborator:
Genentech, Inc.
Treatments:
Carboplatin
Dacetuzumab
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Rituximab